Goldman Sachs
ZVRA icon

Goldman Sachs’s Zevra Therapeutics ZVRA Stock Holding History

Goldman Sachs’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-23,600
Closed -$220K – 7056
2026
Q1 		$220K Hold
23,600
– – ﹤0.01% 6039
2025
Q4 		$211K Buy
+23,600
New +$223K ﹤0.01% 6023

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs's ZVRA Position: Q2 2026 in Review

Goldman Sachs reduced its Zevra Therapeutics (ZVRA) stake by 27% in Q2 2026, selling an estimated $2.2M and leaving 545,551 shares worth $7.82M. The position accounts for ﹤0.01% of the portfolio, ranked #3474.

Goldman Sachs first reported a position in ZVRA in Q4 2015 and has held it in 32 quarters since. 158 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

  • Goldman Sachs held 545,551 shares of Zevra Therapeutics worth $7.82M as of Q2 2026.
  • Goldman Sachs sold 197,573 Zevra Therapeutics shares in Q2 2026, an estimated $2.2M.
  • Zevra Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #3474 holding.
  • Goldman Sachs first reported a position in Zevra Therapeutics in Q4 2015 and has held it in 32 quarters since.
  • 158 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.